Longitudinal data supporting the predictive value of non-invasive MRI biomarkers in kidney disease progression to be presented at ASN Kidney Week

Follow-up data from a collaboration between Antaros Medical, Sahlgrenska University Hospital and AstraZeneca will be presented tomorrow, Thursday November 3rd, at ASN Kidney Week 2022. It will be presented by Paul Hockings (Senior Director MR Imaging at Antaros Medical and Adjunct Professor at Chalmers University of Technology) on behalf of the project team (First author: Kianoush Makvandi, a nephrologist at Sahlgrenska University Hospital) @ 10:00-12:00.

The abstract describes data on a wide range of Magnetic Resonance Imaging (MRI) biomarkers that were evaluated, both at baseline and after two years, and evaluated for their predictive value in discriminating between diabetic kidney disease (DKD) patients with progressive disease and those without (healthy volunteers). The findings suggest that certain imaging biomarkers may be predictors of disease progression, highlighting an exciting path for further research and providing additional support for the growing body of evidence in favour of MRI as a non-invasive tool for evaluating and predicting kidney disease progression.

Find the abstract here.

Abstract title: Multiparametric Magnetic Resonance Imaging allows the prediction of diabetic disease progression
Abstract number: TH-PO228
Authors: Makvandi K, Hockings P, Jensen G, Hulthe J, Haraldsson H, Baid-Agrawal S

Share on Linkedin Share on Twitter